Boston Scientific Begins AVANT GUARD Clinical Trial To Evaluate FARAPULSE Pulsed Field Ablation System As First-Line Treatment For Persistent Atrial Fibrillation

+0.67%

Boston Scientific Corporation

BSX

104.32

+0.67%

The randomized AVANT GUARD trial will enroll more than 500 patients diagnosed with persistent AF at up to 75 sites globally. The company now anticipates U.S. Food and Drug Administration approval of the FARAPULSE PFA System in the first quarter of 2024.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.